Unicycive Therapeutics, Inc.

5150 El Camino Real, Suite A-32

Los Altos, CA 94022

 

  July 8, 2021

 

VIA EDGAR

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jeffrey Gabor

 

Re:       Unicycive Therapeutics, Inc.
  Registration Statement on Form S-1
  Filed May 21, 2021
  File No. 333-256367

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Unicycive Therapeutics, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:00 p.m., Eastern Daylight Time, on Monday, July 12, 2021, or as soon thereafter as possible. 

 

Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (201) 669-0478 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

 

  UNICYCIVE THERAPEUTICS, INC.
   
  By: /s/ Shalabh Gupta
  Name:  Shalabh Gupta
  Title: Chief Executive Officer